Restricted Specificity of Anti-V3 Antibodies Induced in Humans by HIV Candidate Vaccines

No abstract is available for this paper.

• Publication year

  1997

• Venue

  AIDS Research and Human Retroviruses

• Publication date

  1997-11-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1089/aid.1997.13.1471PMID 9390746
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Comparison and fine mapping of both high and low neutralizing monoclonal antibodies against the principal neutralization domain of HIV-1

  2005cited by this paper
• Vaccine-specific antibody responses induced by HIV-1 envelope subunit vaccines.

  1997cited by this paper
• Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group.

  1996cited by this paper
• The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1

  1996cited by this paper
• The V3 domain of the HIV–1 gp120 envelope glycoprotein is critical for chemokine–mediated blockade of infection

  1996cited by this paper
• HIV-1 Entry Cofactor: Functional cDNA Cloning of a Seven-Transmembrane, G Protein-Coupled Receptor

  1996cited by this paper
• In Vitro Effects of Anti-HIV Immunotoxins Directed against Multiple Epitopes on HIV Type 1 Envelope Glycoprotein 160

  1996cited by this paper
• Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation

  1996cited by this paper
• The CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents infection by T-cell-line-adapted HIV-1

  1996cited by this paper
• Identification of a major co-receptor for primary isolates of HIV-1

  1996cited by this paper
• Diversity of the envelope glycoprotein among human immunodeficiency virus type 1 isolates of clade E from Asia and Africa

  1996cited by this paper
• The lymphocyte chemoattractant SDF-1 is a ligand for LESTR/fusin and blocks HIV-1 entry

  1996cited by this paper
• Multiple Immunizations with Attenuated Poxvirus HIV Type 2 Recombinants and Subunit Boosts Required for Protection of Rhesus Macaques

  1996cited by this paper
• CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5

  1996cited by this paper
• A Prime-Boost Approach to HIV Preventive Vaccine Using a Recombinant Canarypox Virus Expressing Glycoprotein 160 (MN) followed by a Recombinant Glycoprotein 160 (MN/LAI)

  1995cited by this paper
• Safety and Immunogenicity of a Recombinant HIV Type 1 Glycoprotein 160 Boosted by a V3 Synthetic Peptide in HIV-Negative Volunteers

  1995cited by this paper
• A prime-boost approach to HIV preventive vaccine using a recombinant canarypox virus expressing glycoprotein 160 (MN) followed by a recombinant glycoprotein 160 (MN/LAI). The AGIS Group, and l'Agence Nationale de Recherche sur le SIDA.

  1995cited by this paper
• Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG

  1995cited by this paper
• Cross-neutralizing activity against divergent human immunodeficiency virus type 1 isolates induced by the gp41 sequence ELDKWAS

  1994cited by this paper
• Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers.

  1994cited by this paper
• Determinants of antibody response after recombinant gp160 boosting in vaccinia-naive volunteers primed with gp160-recombinant vaccinia virus. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Clinical Trials Network.

  1994cited by this paper
• Neutralization of divergent human immunodeficiency virus type 1 variants and primary isolates by IAM-41-2F5, an anti-gp41 human monoclonal antibody.

  1994cited by this paper
• HIV-1 envelope-elicited neutralizing antibody titres correlate with protection and virus load in chimpanzees.

  1994cited by this paper
• Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120.

  1993cited by this paper
• A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1

  1993cited by this paper
• Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.

  1993cited by this paper
• V3-specific neutralizing antibodies in sera from HIV-1 gp160-immunized volunteers block virus fusion and act synergistically with human monoclonal antibody to the conformation-dependent CD4 binding site of gp120. NIH-NIAID AIDS Vaccine Clinical Trials Network.

  1993cited by this paper
• Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.

  1993cited by this paper
• Augmentation of Human Immunodeficiency Virus Type 1 Neutralizing Antibody by Priming with gp160 Recombinant Vaccinia and Boosting with gp160 in Vaccinia-Naive Adults

  1993cited by this paper
• Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells.

  1992cited by this paper
• Serum antibodies to HIV-1 in recombinant vaccinia virus recipients boosted with purified recombinant gp160

  1992cited by this paper
• Prevention of HIV-1 infection in chimpanzees by gpl20 V3 domain-specific monoclonal antibody

  1992cited by this paper
• Neutralization of multiple laboratory and clinical isolates of human immunodeficiency virus type 1 (HIV-1) by antisera raised against gp120 from the MN isolate of HIV-1

  1992cited by this paper
• Prevention of HIV-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody.

  1992cited by this paper
• Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody

  1992cited by this paper
• Neutralizing activity of anti-peptide antibodies against the principal neutralization domain of human immunodeficiency virus type 1.

  1991cited by this paper
• Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.

  1991cited by this paper
• The role of the V3 loop of gp120 in HIV infection.

  1991cited by this paper
• Importance of Hypervariable Regions of HIV-1 gp120 in the Generation of Virus Neutralizing Antibodies

  1990cited by this paper
• Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant.

  1990cited by this paper
• Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160

  1990cited by this paper
• Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

  1989cited by this paper
• Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120.

  1988cited by this paper
• Human antibody response to a strain-specific HIV-1 gp120 epitope associated with cell fusion inhibition.

  1988cited by this paper
• Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind a 24-amino acid sequence of the viral envelope, gp120.

  1988cited by this paper
• Human immunodeficiency virus type 1 neutralization epitope with conserved architecture elicits early type-specific antibodies in experimentally infected chimpanzees.

  1988cited by this paper
• Immunodominant B-cell epitopes of the HIV-1 envelope recognized by infected and immunized hosts.

  1988cited by this paper
• Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptor.

  1987cited by this paper

• Neutralizing activity of antibodies to the V3 loop region of HIV-1 gp120 relative to their epitope fine specificity.

  2008cites this paper
• Group M-based HIV-1 Gag peptides are frequently targeted by T cells in chronically infected US and Zambian patients

  2006cites this paper
• Induced fit in HIV-neutralizing antibody complexes: evidence for alternative conformations of the gp120 V3 loop and the molecular basis for broad neutralization.

  2005cites this paper
• AIDS VACCINE: STATE OF THE ART AT THE BEGINNING OF THE THIRD MILLENNIUM

  2004cites this paper
• Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers

  2001cites this paper
• A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320.

  2000cites this paper
• Structural prerequisites for intersubtype B and D antigenicity of the third variable envelope region (V3) of human immunodeficiency virus type 1.

  2000cites this paper
• Immunologic responses of HIV-1-infected study subjects to immunization with a mixture of peptide protein derivative-V3 loop peptide conjugates

  1999cites this paper
• Comparative studies on neutralisation of primary HIV‐1 isolates by human sera and rabbit anti‐V3 peptide sera

  1999cites this paper
• Immunologic responses of HIV-1-infected study subjects to immunization with a mixture of peptide protein derivative-V3 loop peptide conjugates.

  1999cites this paper
• Fine Specificity of Anti-V3 Antibodies Induced in Chimpanzees by HIV Candidate Vaccines

  1998cites this paper